Ixazomib-Thalidomide-low dose dexamethasone induction followed by maintenance therapy with ixazomib or placebo in newly diagnosed multiple myeloma patients not eligible for autologous stem cell transplantation; results from the randomized phase II HOVON-126/NMSG 21.13 trial

Affiliations

• ¹ Amsterdam University Medical Center, Location VUmc, Amsterdam, the Netherlands.
• ² Stavanger University Hospital-Rogaland Hospital, Stavanger, Norway.
• ³ Oslo Myeloma Center, Oslo, Norway.
• ⁴ Albert Schweitzer Hospital, Dordrecht, the Netherlands.
• ⁵ St Olavs Hospital and Norwegian University of Science, Trondheim, Norway.
• ⁶ Maasstad Hospital, Rotterdam, the Netherlands.
• ⁷ Meander Medical Center, Amersfoort, the Netherlands.
• ⁸ Førde Central Hospital, Førde, Norway.
• ⁹ Skanes University Hospital Lund, Scania, Sweden.
• ¹⁰ Herlev Hospital, Herlev, Denmark.
• ¹¹ NU-Hospital, Uddevalla Hospital, Uddevalla, Sweden.
• ¹² Rijnstate Hospital, Arnhem, the Netherlands.
• ¹³ Aalborg Hospital, Aalborg, Denmark.
• ¹⁴ Aarhus University Hospital, Aarhus, Denmark.
• ¹⁵ Rigshospitalet Copenhagen, Copenhagen, Denmark.
• ¹⁶ Sahlgrenska University Hospital, Gothenburg Sweden.
• ¹⁷ Haga Hospital, Den Haag, the Netherlands.
• ¹⁸ Sodra Alvsborgs Sjukhus Boras, Boras, Sweden.
• ¹⁹ Radboud Medical Center, Nijmegen, the Netherlands.
• ²⁰ Erasmus Medical Center Cancer Institute, Rotterdam, the Netherlands.
• ²¹ Department of Haematology, AgeCare, Odense University Hospital, Odense, Denmark.